From the publishers of JADPRO

Biomarkers in NSCLC Resource Center

Advertisement

Optimizing the Sequencing of Tyrosine Kinase Inhibitors (TKIs) in Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Non-Small Cell Lung Cancer (NSCLC)

Last Updated: Wednesday, June 16, 2021

This review considers the evolving role of sequencing treatments to maximize benefits for patients with EGFR mutation-positive advanced NSCLC.

Lung Cancer
Advertisement
News & Literature Highlights
Advertisement
Advertisement